Observational analysis finds lower risks of end-stage kidney disease in adults with nephrotic-range proteinuria, suggesting kidney protection from SGLT2 inhibitors.
Among adults with T2DM and nephrotic-range proteinuria, SGLT2i versus DPP4i was associated with lower long-term risks of ESKD and all-cause mortality and no clear differences in cardiovascular or safety outcomes were observed. These real-world observational findings support a potential kidney-protective role of SGLT2i in this very high-risk group and complement existing randomized trial data, but dedicated randomized trials in patients with nephrotic-range proteinuria remain necessary.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: